Pictet Asset Management Holding SA Has $32.49 Million Stake in Kiniksa Pharmaceuticals International, plc $KNSA

Pictet Asset Management Holding SA reduced its holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 15.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 787,520 shares of the company’s stock after selling 144,576 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Kiniksa Pharmaceuticals International were worth $32,485,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. UBS Group AG grew its position in Kiniksa Pharmaceuticals International by 56.4% during the 4th quarter. UBS Group AG now owns 77,916 shares of the company’s stock worth $3,214,000 after acquiring an additional 28,099 shares during the last quarter. Sanctuary Advisors LLC bought a new position in Kiniksa Pharmaceuticals International in the 4th quarter valued at $222,000. Vanguard Group Inc. boosted its stake in Kiniksa Pharmaceuticals International by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 3,112,937 shares of the company’s stock worth $128,409,000 after purchasing an additional 49,802 shares in the last quarter. Round Rock Advisors LLC boosted its stake in Kiniksa Pharmaceuticals International by 36.8% in the fourth quarter. Round Rock Advisors LLC now owns 7,055 shares of the company’s stock worth $291,000 after purchasing an additional 1,899 shares in the last quarter. Finally, TD Waterhouse Canada Inc. grew its holdings in shares of Kiniksa Pharmaceuticals International by 461.1% during the fourth quarter. TD Waterhouse Canada Inc. now owns 11,447 shares of the company’s stock worth $471,000 after purchasing an additional 9,407 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors.

Key Kiniksa Pharmaceuticals International News

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Q1 results beat expectations — Kiniksa reported $0.27 EPS vs. consensus $0.18 and revenue of $214.3M (up ~55.5% YoY), driven by ARCALYST product growth. Strong beat and high-margin progress support near-term earnings confidence. Press Release
• Positive Sentiment: FY‑2026 revenue guidance was raised to $930M–$945M vs. Street ~$912.7M — this upward guidance is a direct positive signal for revenue trajectory and model revisions. Guidance Release
• Positive Sentiment: Product momentum: ARCALYST net product revenue reported at $214.3M in Q1 and management increased 2026 ARCALYST expectations — supports revenue durability and valuation multiple expansion. Product Revenue Release
• Positive Sentiment: Pipeline catalysts: KPL‑387 Phase 2 recurrent pericarditis data expected in 2H‑2026 and a Phase 3 pivotal trial anticipated to start by year‑end — upcoming readouts could be meaningful share-price catalysts. Pipeline Release
• Positive Sentiment: Analyst upgrades and price‑target raises — multiple firms lifted targets (Jefferies to $71, Citigroup to $60, Canaccord to $64, Wedbush to $59, Wells Fargo to $57), reflecting higher revenue/earnings expectations and driving buy-side interest. Analyst Coverage More Analyst Notes
• Neutral Sentiment: Company materials and call: Q1 earnings slide deck and transcript are available for investors who want detail on channel dynamics, margins and guidance assumptions. Use these to validate the upbeat narrative. Earnings Presentation Call Transcript
• Negative Sentiment: Insider sale: Director Barry D. Quart sold 13,099 shares (~$50.10 avg) under a pre‑arranged Rule 10b5‑1 plan, reducing his stake ~51%. While pre‑planned, insider selling can still weigh on sentiment and may contribute to near‑term price pressure. SEC Filing Insider Trade Detail

Kiniksa Pharmaceuticals International Stock Performance

NASDAQ KNSA opened at $52.99 on Thursday. The stock has a market capitalization of $4.06 billion, a P/E ratio of 71.61 and a beta of 0.06. Kiniksa Pharmaceuticals International, plc has a 52 week low of $24.85 and a 52 week high of $54.31. The stock has a fifty day moving average of $46.26 and a 200-day moving average of $43.04.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.09. The business had revenue of $214.27 million for the quarter, compared to analyst estimates of $207.12 million. Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.The firm’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.11 earnings per share. Equities research analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.09 earnings per share for the current fiscal year.

Insider Activity

In other Kiniksa Pharmaceuticals International news, CFO Mark Ragosa sold 17,845 shares of the company’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $43.28, for a total transaction of $772,331.60. Following the transaction, the chief financial officer directly owned 12,086 shares in the company, valued at approximately $523,082.08. This represents a 59.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Barry D. Quart sold 13,099 shares of the firm’s stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $50.10, for a total transaction of $656,259.90. Following the completion of the transaction, the director directly owned 12,546 shares in the company, valued at $628,554.60. This trade represents a 51.08% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 74,578 shares of company stock worth $3,489,072. Corporate insiders own 53.48% of the company’s stock.

Analysts Set New Price Targets

KNSA has been the subject of a number of research reports. Zacks Research lowered Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research note on Friday, April 17th. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a “buy” rating to a “hold” rating in a research report on Sunday. Weiss Ratings reissued a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Tuesday, April 21st. Citigroup raised their price objective on shares of Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Wedbush boosted their target price on shares of Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the stock an “outperform” rating in a research note on Wednesday. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $60.86.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.